Citations 92

Essential Tremor in the Elderly and Risk for Dementia

Journal of Neurodegenerative Diseases | April 22, 2014 | Volume: 2014 | Issue: No issue available | Pages: 1-5

10.1155/2014/328765 | PMID 26317006

The objective is to examine the risk of dementia in subjects with essential tremor (ET) involved in the Arizona Study of Aging and Neurodegenerative Disorders. All subjects were free of a neurodegenerative diagnosis at baseline and had annual motor, general neurological, and neuropsychological assessments. Subjects with ET were compared with controls for the risk of dementia. There were 83 subjects with ET and 424 subjects without tremor. Mean age at study entry was 80±5.9 for ET and 76±8.5 for controls. Median tremor duration was 5.2 years at study entry. Followup was a median of 5.4 years (range 0.9 to 12.1). The hazard ratio for the association between ET and dementia was 0.79 (95% CI 0.33 to 1.85). The hazard ratio for the association between tremor onset at age 65 or over, versus onset before age 65, was 2.1 (95% CI 0.24 to 18) and the hazard ratio for the association between tremor duration greater than 5 years, versus less than 5 years, was 0.46 (95% CI 0.08 to 2.6). We conclude that all elderly ET was not associated with an increased risk of dementia but that a subset of subjects with older age onset/shorter duration tremor may be at higher risk.
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease

JAMA Neurology | March 25, 2014 | Volume: 71 | Issue: 5 | Pages: 543

10.1001/jamaneurol.2014.131 | PMID 24664227

Essential tremor is not associated with cerebellar Purkinje cell loss

Movement Disorders | February 17, 2014 | Volume: 29 | Issue: 4 | Pages: 496-500

10.1002/mds.25845 | PMID 24532134

ABSTRACT There has been controversy as to whether there is an underlying neurodegenerative process of the cerebellum in essential tremor (ET). The aim of this study was to examine whether ET is associated with Purkinje cell (PC) loss. Prospectively categorized ET and control subjects who were longitudinally examined in the Arizona Study for Aging and Neurodegenerative Disorders and came to autopsy between 1998 and 2013 underwent standardized neuropathological assessment of the brain. PC linear density of the cerebellar hemisphere was calculated in a blinded manner. There were 56 ET cases and 62 age‐matched controls free of dementia and other neurodegenerative disorders included in the study. Mean PC linear density was 3.80 ± 0.81 cells per mm for tremor cases and 3.82 ± 0.91 cells per mm for controls ( Δ 0.02; 95% confidence interval [CI]: −0.30‐0.34). PC counts were not associated with tremor duration (r = 0.06; 95% CI: −0.21‐0.32). These data demonstrate that ET is not associated with cerebellar PC loss. © 2014 International Parkinson and Movement Disorder Society
Submandibular gland needle biopsy for the diagnosis of Parkinson disease

Neurology | February 6, 2014 | Volume: 82 | Issue: 10 | Pages: 858-864

10.1212/wnl.0000000000000204 | PMID 24500652

O2–10–06: Neuropathological outcome of prospectively followed normal elderly brain bank volunteers

Alzheimer's & Dementia | October 9, 2013 | Volume: 9 | Issue: 4S_Part_8 | Pages: No page available

10.1016/j.jalz.2013.04.194

Quantitative Appraisal of Ventricular Cerebrospinal Fluid Biomarkers in Neuropathologically Diagnosed Parkinson's Disease Cases Lacking Alzheimer's Disease Pathology

Biomarker Insights | March 12, 2013 | Volume: 8 | Issue: No issue available | Pages: BMI.S11422

10.4137/bmi.s11422 | PMID 23533154

Identifying biomarkers that distinguish Parkinson's disease (PD) from normal control (NC) individuals has the potential to increase diagnostic sensitivity for the detection of early-stage PD. A previous proteomic study identified potential biomarkers in postmortem ventricular cerebrospinal fluid (V-CSF) from neuropathologically diagnosed PD subjects lacking Alzheimer's disease (AD) neuropathology. In the present study, we assessed these biomarkers as well as p-tau 181 , Aβ42, and S100B by ELISA in PD (n = 43) and NC (n = 49) cases. The p-tau 181 /Aβ42 ratio and ApoA-1 showed statistically significant differences between groups. Multiple regression analysis demonstrated that p-tau 181 /Aβ42 had a significant odds ratio: OR = 1.42 (95% confidence interval [CI], 1.12–1.84), P = 0.006. Among the molecules investigated, intriguing correlations were observed that require further investigation. Our results suggest coexistent AD CSF biomarkers within the PD group notwithstanding that it was selected to minimize AD neuropathological lesions.
Bid signal pathway components are identified in the temporal cortex with Parkinson disease

Neurology | September 27, 2012 | Volume: 79 | Issue: 17 | Pages: 1767-1773

10.1212/wnl.0b013e3182703f76 | PMID 23019260

Cerebrospinal fluid biomarkers of neuropathologically diagnosed Parkinson’s disease subjects

Neurological Research | August 14, 2012 | Volume: 34 | Issue: 7 | Pages: 669-676

10.1179/1743132812y.0000000063 | PMID 22889670

Essential Tremor is Not a Neurodegenerative Disease

Neurodegenerative Disease Management | June 18, 2012 | Volume: 2 | Issue: 3 | Pages: 259-268

10.2217/nmt.12.23 | PMID 23105950

Quantitative EEG as a predictive biomarker for Parkinson disease dementia

Neurology | June 3, 2011 | Volume: 77 | Issue: 2 | Pages: 118-124

10.1212/wnl.0b013e318224af8d | PMID 21633128